Clovis Oncology’s stock surges after positive clinical results

Facebook Twitter Google+ LinkedIn Email PrintBOULDER — Clovis Oncology Inc. (Nasdaq: CLVS), a biotech firm specializing in cancer research, is seeing a surge in its stock. The company’s stock gained 50 percent prior to the market opening on Monday, after its late-stage cancer drug trial met its goals. The biotech firm now plans to file for approval for the drug, rucaparib, from the U.S. Food and Drug Administration within the next four months. Rucaparib is geared…